BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32382048)

  • 1. Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning.
    Liu S; Shah Z; Sav A; Russo C; Berkovsky S; Qian Y; Coiera E; Di Ieva A
    Sci Rep; 2020 May; 10(1):7733. PubMed ID: 32382048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generative AI in glioma: Ensuring diversity in training image phenotypes to improve diagnostic performance for IDH mutation prediction.
    Moon HH; Jeong J; Park JE; Kim N; Choi C; Kim YH; Song SW; Hong CK; Kim JH; Kim HS
    Neuro Oncol; 2024 Jun; 26(6):1124-1135. PubMed ID: 38253989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
    J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
    Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
    J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Intra- and Inter-Modality Fusion Model Using MR Images for Prediction of Glioma Isocitrate Dehydrogenase (IDH) Mutation.
    Shi X; Zhang X; Iwamoto Y; Cheng J; Bai J; Zhao G; Chen YW
    Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():198-202. PubMed ID: 36086447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
    Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
    AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.
    Kern M; Auer TA; Fehrenbach U; Tanyildizi Y; Picht T; Misch M; Wiener E
    Neuroradiol J; 2020 Apr; 33(2):160-168. PubMed ID: 31957551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generative adversarial network for glioblastoma ensures morphologic variations and improves diagnostic model for isocitrate dehydrogenase mutant type.
    Park JE; Eun D; Kim HS; Lee DH; Jang RW; Kim N
    Sci Rep; 2021 May; 11(1):9912. PubMed ID: 33972663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of IDH and TERTp mutations using dynamic susceptibility contrast MRI with deep learning in 162 gliomas.
    Buz-Yalug B; Turhan G; Cetin AI; Dindar SS; Danyeli AE; Yakicier C; Pamir MN; Özduman K; Dincer A; Ozturk-Isik E
    Eur J Radiol; 2024 Jan; 170():111257. PubMed ID: 38134710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas.
    Bangalore Yogananda CG; Shah BR; Vejdani-Jahromi M; Nalawade SS; Murugesan GK; Yu FF; Pinho MC; Wagner BC; Mickey B; Patel TR; Fei B; Madhuranthakam AJ; Maldjian JA
    Neuro Oncol; 2020 Mar; 22(3):402-411. PubMed ID: 31637430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
    Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
    Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis.
    Zhao J; Huang Y; Song Y; Xie D; Hu M; Qiu H; Chu J
    Eur Radiol; 2020 Aug; 30(8):4664-4674. PubMed ID: 32193643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
    Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
    Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.
    Peng H; Huo J; Li B; Cui Y; Zhang H; Zhang L; Ma L
    J Magn Reson Imaging; 2021 May; 53(5):1399-1407. PubMed ID: 33179832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
    Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
    Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
    Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined texture analysis of dynamic contrast-enhanced MRI with histogram analysis of diffusion kurtosis imaging for predicting IDH mutational status in gliomas.
    Pan T; Su CQ; Tang WT; Lin J; Lu SS; Hong XN
    Acta Radiol; 2023 Sep; 64(9):2552-2560. PubMed ID: 37331987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine learning: a useful radiological adjunct in determination of a newly diagnosed glioma's grade and IDH status.
    De Looze C; Beausang A; Cryan J; Loftus T; Buckley PG; Farrell M; Looby S; Reilly R; Brett F; Kearney H
    J Neurooncol; 2018 Sep; 139(2):491-499. PubMed ID: 29770897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.